Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Undifferentiated pleomorphic sarcoma of the cornea: case report

Poster Details

First Author: A. Budnik POLAND

Co Author(s):    L. Lisowski   J. Reszec   Z. Mariak              

Abstract Details

Purpose:

To report a case of undifferentiated pleomorphic sarcoma of the cornea and literature review.

Setting:

Department of Ophthalmology, Medical University of Bialystok Clinical Hospital, Bialystok, Poland.

Methods:

A 91-year-old female presented with rapidly increased tumor in inferior temporal quadrant of the cornea in the right eye, extended to the bulbar conjunctiva caused lagophthalmos and decreased visual acuity. Tumor markers and chest X-ray were carried out in order to search for the primary tumor and metastases. Optical coherence tomography and ultrabiomicroscopic were performed to evaluate of the depth tumor infiltration of anterior segment of the eyeball. The tumor was excised in its entirety. The subsequent coagulation of the supply vessels and application of ethanol 96% were applied.

Results:

The histological investigation revealed an undifferentiated pleomorphic sarcoma. The postoperative course was uneventful. Laboratory tests showed elevated level of a serum pro-gastrin-releasing peptide (proGRP) and neuron-specific enolase (NSE). A chest X-ray was negative. We observed visual acuity improvement and resolution of symptoms after surgery. Considering her advanced age and comorbid diseases, the patient refused consent to expanded diagnosis and treatment.

Conclusions:

A review of the literature confirms this is the first reported case of undifferentiated pleomorphic sarcoma of the cornea. Surgical excision is likely the most appropriate treatment option.

Financial Disclosure:

NONE

Back to Poster listing